Peripheral Neuropathy Still Common Among HIV-Infected Patients on HAART; Risk May Increase With Age (February 10, 2009)
A metastudy of ACTG trial participants finds peripheral neuropathy prevalence of greater than 20% among patients initiating HAART -- a proportion that increases as patients age, despite maintaining a CD4+ cell count above 350 and a viral load below 400, and despite declining use of didanosine and stavudine. Study presenter Scott Evans, Ph.D., also notes that neuropathy usually occurred without patients experiencing any pain whatsoever.
In The 16th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO
TheBody is a service of Remedy Health Media, 461 Fifth Avenue, 14th Floor, New York, NY 10017. TheBody and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBody's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBody is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.